PK
Panagiotis Konstantinopoulos
Dana-Farber Cancer Institute
Research areas: Medicine · Oncology · Ovarian cancer diagnosis and treatment · PARP inhibition in cancer therapy · BRCA gene mutations in cancer
0000-0002-1032-1479
Employment
- 2021 - Present
Education
Education history is unavailable.
Projects & Funding
Projects & funding information is unavailable.
Publications (286)
- Comparative analysis of microRNA expression in serum and plasma in patients screened for BRCA1 or BRCA2 mutations Save
- Phase II clinical trial of nirogacestat in patients with relapsed ovarian granulosa cell tumours Save
- Letrozole, abemaciclib and metformin in endometrial cancer: a non-randomized phase 2 trial Save
- Primary Analysis of EPIK-O/ENGOT-ov61: Alpelisib Plus Olaparib Versus Chemotherapy in Platinum-Resistant or Platinum-Refractory High-Grade Serous Ovarian Cancer Without BRCA Mutation Save
- A working group report from the 2024 National Cancer Institute / Gynecologic Cancer Steering Committee endometrial cancer clinical trials planning meeting: refining the approach to endometrial cancer in the immunotherapy era Save
- PIK3CB Inhibitor GSK2636771 in Cancers With PTEN Mutation/Deletion or Loss of PTEN Protein Expression: Results From the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocols N and P Save
- Serial Circulating Tumor DNA Sequencing to Monitor Response and Define Acquired Resistance to Letrozole/Abemaciclib in Endometrial Cancer Save
- A phase I clinical trial of radiation therapy, durvalumab and tremelimumab in recurrent gynecologic cancer Save
- EFFORT2: COMBINATION CERALASERTIB (ATRI) PLUS OLAPARIB (PARPI) IN WOMEN WITH PLATINUM SENSITIVE HOMOLOGOUS RECOMBINATION DEFICIENT (HRD) OVARIAN CANCER WITH PRIOR PARPI EXPOSURE Save
- Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8+ and PD-1+ Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk Factors Save
- PTEN protein and lipid phosphatase deficiency confers sensitivity to ATR inhibitor-based treatment in high-grade serous ovarian cancer Save
- Phase 2 study of Wee1 inhibitor adavosertib in recurrent uterine carcinosarcoma Save
- Phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient recurrent or persistent endometrial cancer Save
- Phase II study of letrozole, abemaciclib and metformin in estrogen receptor-positive recurrent endometrial cancer Save
- Role of adjuvant radiotherapy modality on clinical outcomes for early-stage uterine carcinosarcoma Save
- 53BP1 loss elicits cGAS-STING-dependent antitumor immunity in ovarian and pancreatic cancer Save
- 53BP1 loss mediated PARP inhibitor resistance in BRCA1-deficient pancreatic cancer is overcome with immune checkpoint blockade Save
- A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) recurrent or persistent endometrial cancer Save
- A phase II trial of pembrolizumab and lenvatinib in recurrent or persistent clear cell ovarian carcinoma (NCT05296512): stage 1 results Save
- A phase II, open-label, multicenter, basket study of the ATR kinase inhibitor ART0380 administered orally as monotherapy to patients with biologically selected advanced or metastatic solid tumors (ARTIST) Save